Lutikizumab
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hidradenitis Suppurativa
Conditions
Hidradenitis Suppurativa, Atopic Dermatitis
Trial Timeline
Aug 14, 2024 → Feb 1, 2027
NCT ID
NCT06524635About Lutikizumab
Lutikizumab is a phase 2 stage product being developed by AbbVie for Hidradenitis Suppurativa. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06524635. Target conditions include Hidradenitis Suppurativa, Atopic Dermatitis.
What happened to similar drugs?
1 of 20 similar drugs in Hidradenitis Suppurativa were approved
Approved (1) Terminated (0) Active (19)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06524635 | Phase 2 | Recruiting |
Competing Products
20 competing products in Hidradenitis Suppurativa
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sonelokimab | MoonLake Immunotherapeutics | Phase 3 | 41 |
| Sonelokimab | MoonLake Immunotherapeutics | Phase 3 | 41 |
| Sonelokimab + Placebo | MoonLake Immunotherapeutics | Phase 3 | 38 |
| Sonelokimab + Placebo | MoonLake Immunotherapeutics | Phase 3 | 38 |
| Sonelokimab (M1095) + Adalimumab | MoonLake Immunotherapeutics | Phase 2 | 29 |
| Eltrekibart + Placebo | Eli Lilly | Phase 2 | 39 |
| Placebo + LY3041658 | Eli Lilly | Phase 2 | 35 |
| Placebo + Adalimumab | AbbVie | Approved | 43 |
| Lutikizumab + Placebo | AbbVie | Phase 3 | 47 |
| Adalimumab | AbbVie | Pre-clinical | 26 |
| Upadacitinib + Placebo | AbbVie | Phase 3 | 47 |
| adalimumab + placebo | AbbVie | Phase 3 | 40 |
| adalimumab | AbbVie | Phase 3 | 40 |
| Lutikizumab + Placebo | AbbVie | Phase 2 | 39 |
| Risankizumab + Placebo for risankizumab | AbbVie | Phase 2 | 35 |
| adalimumab | AbbVie | Phase 3 | 40 |
| adalimumab + placebo | AbbVie | Phase 3 | 40 |
| Upadacitinib + Placebo | AbbVie | Phase 2 | 35 |
| MEDI8968 + Saline | AstraZeneca | Phase 2 | 27 |
| Anifrolumab | AstraZeneca | Phase 2 | 39 |